Caisse DE Depot ET Placement DU Quebec Makes New Investment in Edwards Lifesciences Corporation $EW

Key Points

• Caisse DE Depot ET Placement DU Quebec has made a new investment of $619,000 in Edwards Lifesciences Corporation, acquiring 8,542 shares during the first quarter.
• Edwards Lifesciences reported strong quarterly earnings, with $1.53 billion in revenue and earnings per share of $0.67, exceeding analysts' expectations.
• Research analysts have a generally positive outlook on the stock, with Barclays increasing their price objective from $90.00 to $95.00 and multiple ratings upgrades from various firms.

Caisse DE Depot ET Placement DU Quebec acquired a new position in Edwards Lifesciences Corporation (NYSE:EW - Free Report) during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 8,542 shares of the medical research company's stock, valued at approximately $619,000.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Brighton Jones LLC acquired a new stake in shares of Edwards Lifesciences during the fourth quarter worth $266,000. Bank Pictet & Cie Europe AG raised its position in shares of Edwards Lifesciences by 16.7% during the fourth quarter. Bank Pictet & Cie Europe AG now owns 10,231 shares of the medical research company's stock worth $757,000 after purchasing an additional 1,463 shares during the period. Integrated Wealth Concepts LLC raised its position in shares of Edwards Lifesciences by 23.4% during the fourth quarter. Integrated Wealth Concepts LLC now owns 9,790 shares of the medical research company's stock worth $725,000 after purchasing an additional 1,856 shares during the period. AQR Capital Management LLC raised its position in shares of Edwards Lifesciences by 43.5% during the fourth quarter. AQR Capital Management LLC now owns 208,889 shares of the medical research company's stock worth $15,464,000 after purchasing an additional 63,313 shares during the period. Finally, Keel Point LLC raised its position in shares of Edwards Lifesciences by 25.4% during the fourth quarter. Keel Point LLC now owns 4,814 shares of the medical research company's stock worth $356,000 after purchasing an additional 976 shares during the period. Institutional investors own 79.46% of the company's stock.

Edwards Lifesciences Price Performance

EW stock traded down $0.24 during midday trading on Thursday, reaching $80.98. 2,501,007 shares of the company's stock traded hands, compared to its average volume of 3,587,524. The company has a 50-day simple moving average of $78.71 and a two-hundred day simple moving average of $75.17. Edwards Lifesciences Corporation has a 1-year low of $64.00 and a 1-year high of $83.00. The company has a market cap of $47.55 billion, a price-to-earnings ratio of 11.65, a PEG ratio of 3.92 and a beta of 1.07. The company has a quick ratio of 3.87, a current ratio of 4.68 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW - Get Free Report) last released its earnings results on Thursday, July 24th. The medical research company reported $0.67 EPS for the quarter, beating the consensus estimate of $0.62 by $0.05. The company had revenue of $1.53 billion during the quarter, compared to analysts' expectations of $1.49 billion. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.The business's revenue for the quarter was up 11.9% on a year-over-year basis. During the same period last year, the firm earned $0.70 EPS. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. On average, analysts anticipate that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the company. Deutsche Bank Aktiengesellschaft boosted their target price on Edwards Lifesciences from $85.00 to $94.00 and gave the stock a "buy" rating in a research report on Friday, July 25th. Wells Fargo & Company lifted their price target on Edwards Lifesciences from $84.00 to $88.00 and gave the company an "overweight" rating in a report on Thursday, August 7th. Dbs Bank upgraded Edwards Lifesciences to a "hold" rating in a report on Monday, June 2nd. William Blair upgraded Edwards Lifesciences to a "strong-buy" rating in a report on Friday, July 25th. Finally, BTIG Research upgraded Edwards Lifesciences from a "neutral" rating to a "buy" rating and set a $100.00 price target on the stock in a report on Tuesday, July 29th. Three equities research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, ten have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $85.90.

Insider Buying and Selling at Edwards Lifesciences

In other news, insider Larry L. Wood sold 8,950 shares of Edwards Lifesciences stock in a transaction on Monday, August 18th. The stock was sold at an average price of $78.06, for a total value of $698,637.00. Following the completion of the sale, the insider directly owned 206,900 shares of the company's stock, valued at approximately $16,150,614. This trade represents a 4.15% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Daniel J. Lippis sold 4,114 shares of Edwards Lifesciences stock in a transaction on Monday, July 28th. The stock was sold at an average price of $79.46, for a total value of $326,898.44. Following the sale, the vice president directly owned 22,002 shares of the company's stock, valued at approximately $1,748,278.92. This trade represents a 15.75% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 22,014 shares of company stock valued at $1,698,844 over the last three months. Insiders own 1.29% of the company's stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.